E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
CNS lymphoma (CNSL) being treated with HD-MTX in patients with impaired renal function |
Patienten mit Lymphomen des Zentralnervensystems und mit eingeschränkter Nierenfunktion, die mit hochdosiertem Methotrexat behandelt werden |
|
E.1.1.1 | Medical condition in easily understood language |
Malignant disease of the lymphatic system in the area of the brain and/or spinal cord with impaired kidney function |
Bösartige Erkrankung des lymphatischen Systems im Bereich des Gehirns und/oder des Rückenmarks mit eingeschränkter Nierenfunktion |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To demonstrate tolerability of intended intervention with VoraxazeTM, in addition to LV, in patients with renal impairment or renal failure during previous HD-MTX therapy. • To measure the efficacy of VoraxazeTM in lowering the MTX blood levels in patients who are being treated with HD-MTX and LV. • To demonstrate the feasibility and safety of escalating doses of HD-MTX in patients with renal impairment or renal failure by use of intended intervention with VoraxazeTM, in addition to LV. • To assess the immunological response to Voraxaze after repeated use and the effect of any response on the safety and efficacy of VoraxazeTM. • To describe levels of MTX and DAMPA in plasma (and CSF in selected patients) following Voraxaze administration. • To assess tolerability of HD-MTX in patients with renal impairment or renal failure in the setting of Voraxaze administration.
|
|
E.2.2 | Secondary objectives of the trial |
- To demonstrate the feasibility and potential benefit of escalating doses of HD-MTX in patients by use of intended intervention with Voraxaze, in addition to LV - To assess the immunological response to Voraxaze after repeated use and the effect of any response on the safety and efficacy of Voraxaze - To demonstrate that HD-MTX with VoraxazeTM allows schedule adherence with 6 cycles HD-MTX |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Primary or secondary CNSL (PCNSL or SCNSL) confirmed by histology or cytology. • Renal insufficiency defined as a glomerular filtration rate (GFR, assessed by CKD-EPI or MDRD equation) of 40-80 mL/min or patients with a GFR >80mL/min who have experienced renal failure, defined as doubling of the serum creatinine compared to the baseline value during a previous HD-MTX treatment. • Age ≥ 18 years (male or female). • Life expectancy >3 months. • Adequate organ function (i.e., bone marrow, liver, lungs) allowing intensive chemotherapy with MTX. • Adequate clinical pathology values: o - Absolute neutrophil count ≥1.0 x 109/L, hemoglobin ≥9mg/dL (transfusion allowed), platelets ≥100 x 109/L. o - Total bilirubin ≤1.5x the upper limit of normal except for patients with known Gilbert syndrome. o - Alanine amino-transferase (ALT) and aspartate amino-transferase (AST) ≤2x the upper limit of normal. o - Alkaline phosphatase ≤2x the upper limit of normal. o - Prothrombin time within the normal range for the institution. • Signed informed consent by the patient or legal representative prior to start of any study specific procedure. • Females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study in such a manner that the risk of pregnancy is minimized. Acceptable contraceptives include intra-uterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable). |
|
E.4 | Principal exclusion criteria |
• Ongoing or expected need for therapy with drugs interfering with MTX-clearance (i.e., beta-lactam antibiotics, NSAIDs, probenicid, salicylates, sulphonamides) or other nephrotoxic drugs. • Prior brain radiotherapy within 28 days of first dose of the study drug. • Concurrent illness interfering with hydration (i.e., relevant congestive heart failure, SIADH syndrome). • Relevant third space (i.e., pleural effusion, ascites, extended edema) precluding HD-MTX treatment. • Obesity (body mass index >30 kg/m2). • Uncontrolled diabetes. • Active hepatitis. • HIV-infection. • Pregnant or lactating woman. • Participation in any other clinical trial either 1 month prior to or during this study. • Previous intolerance to any of the drugs used in this study (i.e., MTX, LV) • The person concerned has been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities • Persons who may be dependent on the sponsor or investigator.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• To demonstrate tolerability (i.e. absence of severe non-hematological toxicity) of intended intervention with repeated doses of VoraxazeTM, in addition to leucovorin (LV), in patients with renals impairment or renal failure during previous HD-MTX therapy. • To measure the efficacy of VoraxazeTM in patients with renal impairment or renal failure who are being treated with HD-MTX and LV as determined by plasma MTX level reduction.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During visits at defined timepoints as per protocol |
|
E.5.2 | Secondary end point(s) |
• To demonstrate the feasibility and potential benefit of escalating doses of HD-MTX in patients by use of intended intervention with VoraxazeTM, in addition to LV. • To assess the immunological response to VoraxazeTM after repeated use and the effect of any response on the safety and efficacy of VoraxazeTM. • To demonstrate that HD-MTX with VoraxazeTM allows schedule adherence with 6 cycles HD-MTX
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During visits at defined timepoints as per protocol |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |